JP Morgan Chase’s Revance Therapeutics, Inc. RVNC Stock Holding History

JP Morgan Chase’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-15,700	Closed	-$180K	–	7949
2023 Q3	$180K	Buy	+15,700	New	+$302K	﹤0.01%	5127
2022 Q2	–	Sell	-4,600	Closed	-$90K	–	6973
2022 Q1	$90K	Buy	+4,600	New	+$69.8K	﹤0.01%	5557

Other funds holding RVNC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

JP Morgan Chase's RVNC Position: Q1 2025 in Review

JP Morgan Chase sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 1,298,822 shares — an estimated $3.95M sold.

JP Morgan Chase first reported a position in RVNC in Q1 2014 and held it in 44 quarters. The position peaked at $166M in Q1 2023. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

JP Morgan Chase reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
JP Morgan Chase sold 1,298,822 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $3.95M.
JP Morgan Chase first reported a position in Revance Therapeutics, Inc. in Q1 2014 and held it in 44 quarters.
JP Morgan Chase's Revance Therapeutics, Inc. position peaked at $166M in Q1 2023.
1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on JP Morgan Chase's 13F filing for Q1 2025, filed 12 May 2025.